BeyondSpring Reports Plinabulin Plus Docetaxel Improves Survival in EGFR Wild-Type NSCLC After Checkpoint Inhibitor Failure
I'm PortAI, I can summarize articles.
BeyondSpring Inc. announced positive results from its Phase 3 DUBLIN-3 Study, showing Plinabulin plus docetaxel improves survival in EGFR wild-type NSCLC patients after checkpoint inhibitor failure. The combination showed better overall survival, progression-free survival, and response rates compared to docetaxel alone. BeyondSpring plans a Phase 3 DUBLIN-4 trial to support a new drug application.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments